ZA200605526B - Substituted azole derivatives, compositions and methods of use - Google Patents

Substituted azole derivatives, compositions and methods of use Download PDF

Info

Publication number
ZA200605526B
ZA200605526B ZA200605526A ZA200605526A ZA200605526B ZA 200605526 B ZA200605526 B ZA 200605526B ZA 200605526 A ZA200605526 A ZA 200605526A ZA 200605526 A ZA200605526 A ZA 200605526A ZA 200605526 B ZA200605526 B ZA 200605526B
Authority
ZA
South Africa
Prior art keywords
phenyl
alkyl
alkylene
dichloro
imidazol
Prior art date
Application number
ZA200605526A
Other languages
English (en)
Inventor
Adnan M M Mjalli
Dharma R Polisetti
Subramanian Govindan
J R James C Quada
Murty N Arimilli
Ravindra R Yarragunta
Robert C Andrews
Xie Rongyan
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of ZA200605526B publication Critical patent/ZA200605526B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200605526A 2004-02-12 2005-02-11 Substituted azole derivatives, compositions and methods of use ZA200605526B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54397104P 2004-02-12 2004-02-12

Publications (1)

Publication Number Publication Date
ZA200605526B true ZA200605526B (en) 2007-11-28

Family

ID=34885991

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605526A ZA200605526B (en) 2004-02-12 2005-02-11 Substituted azole derivatives, compositions and methods of use

Country Status (10)

Country Link
US (2) US20050187277A1 (de)
EP (1) EP1730118A1 (de)
JP (1) JP4898458B2 (de)
CN (1) CN1922151A (de)
AU (1) AU2005214349B2 (de)
CA (1) CA2551909C (de)
IL (1) IL176571A0 (de)
NZ (1) NZ548208A (de)
WO (1) WO2005080346A1 (de)
ZA (1) ZA200605526B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087748A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
EP1722787A4 (de) * 2004-03-08 2007-09-26 Wyeth Corp Ionenkanal-modulatoren
KR101128065B1 (ko) * 2004-05-26 2012-04-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
KR101170925B1 (ko) 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ksp) 억제제로서의n-(1-(1-벤질-4-페닐-1h-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
AU2005297966B2 (en) 2004-10-26 2010-12-23 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
US20060199853A1 (en) * 2005-02-18 2006-09-07 Charles Mioskowski Analogs of 4-hydroxyisoleucine and uses thereof
WO2006131836A2 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
WO2007058304A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
WO2007058305A1 (ja) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド誘導体の製造方法
NZ568050A (en) * 2005-11-24 2010-09-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
CN101374835B (zh) * 2006-01-30 2012-04-25 转化技术制药公司 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AR059955A1 (es) * 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007107008A1 (en) * 2006-03-22 2007-09-27 Innodia Inc. Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
SA07280403B1 (ar) * 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
CA2666310C (en) * 2006-10-20 2012-07-31 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
AU2007309568A1 (en) * 2006-10-20 2008-05-02 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
CA2667003A1 (en) * 2006-10-20 2008-05-02 Merck & Co., Inc. Substituted imidazoles as bombesin receptor subtype-3 modulators
EP2102201B1 (de) * 2006-12-11 2010-10-13 Merck Sharp & Dohme Corp. Substituierte diazepin-sulfonamide als bombesin-rezeptor-subtyp-3-modulatoren
JP2010515687A (ja) * 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤(eg−5)としてのイミダゾール誘導体
TW200848054A (en) * 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
JPWO2008140111A1 (ja) * 2007-05-16 2010-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド誘導体のワンポット製造方法
MX2010002098A (es) * 2007-08-31 2010-03-30 Eisai R&D Man Co Ltd Compuesto policiclico.
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CA2712095A1 (en) * 2008-01-28 2009-08-06 Eisai R&D Management Co., Ltd. Crystalline cinnamide compounds or salts thereof
MX2011003239A (es) * 2008-09-26 2011-04-28 Merck Sharp & Dohme Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
KR101602985B1 (ko) * 2008-10-06 2016-03-11 시코쿠가세이고교가부시키가이샤 2-벤질-4-(2,4-디클로로페닐)-5-메틸이미다졸 화합물
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
AU2010243353B2 (en) 2009-04-30 2014-09-11 Astex Therapeutics Limited Imidazole derivatives and their use as modulators of Cyclin dependent Kinases
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 2−(2,4−ジクロロベンジル)−4−アリール−5−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 4−(2,4−ジクロロフェニル)−5−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 4−(4−ビフェニリル)−2−(2,4−ジクロロベンジル)イミダゾールおよび表面処理液
JP5398076B2 (ja) * 2009-12-10 2014-01-29 四国化成工業株式会社 2−(ブロモベンジル)−4−(ブロモフェニル)−5−メチルイミダゾール化合物
JP5398075B2 (ja) * 2010-01-13 2014-01-29 四国化成工業株式会社 4−(ジクロロフェニル)−2−(4−フルオロベンジル)−5−メチルイミダゾール化合物
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2012139010A1 (en) * 2011-04-08 2012-10-11 University Of Kansas Grp94 inhibitors
WO2014123203A1 (ja) * 2013-02-06 2014-08-14 京都薬品工業株式会社 糖尿病治療薬
DK3013796T3 (da) * 2013-06-27 2020-03-16 Lg Chemical Ltd Biarylderivater som gpr120-agonister
WO2015120610A1 (en) * 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CN109825849B (zh) * 2019-01-25 2021-02-19 华南理工大学 一种三氟甲基乙烯基类化合物的电化学制备方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546113A (en) * 1983-04-14 1985-10-08 Pfizer Inc. Antiprotozoal diamidines
DE69026851T2 (de) * 1989-02-14 1996-10-31 Wako Pure Chem Ind Ltd Verfahren zur Erhöhung von Chemilumineszenz
WO1993018029A1 (en) * 1992-03-13 1993-09-16 Merck Sharp & Dohme Limited Imidazole, triazole and tetrazole derivatives
WO1994008982A1 (en) * 1992-10-13 1994-04-28 Nippon Soda Co., Ltd. Oxazole and thiazole derivatives
ES2157991T3 (es) * 1993-09-14 2001-09-01 Merck & Co Inc Cadn que codifica una nueva proteina humana, la tirosin-fosfatasa.
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
DE69635048T2 (de) * 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
US6388076B1 (en) * 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
US6238902B1 (en) * 1996-03-22 2001-05-29 Genentech, Inc. Protein tyrosine phosphatases
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
AU9253798A (en) * 1997-09-23 1999-04-12 Novo Nordisk A/S Modules of protein tyrosine phosphatases (ptpases)
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
AU4072799A (en) * 1998-05-12 1999-12-13 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
US20030194745A1 (en) * 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
US6605753B1 (en) * 1998-07-24 2003-08-12 Merck & Co., Inc. Protein tyrosine phosphate-1B (PTP-1B) deficient mice and uses thereof
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
AU1543600A (en) * 1998-12-11 2000-07-03 Mcgill University Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
JP4221129B2 (ja) * 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
CA2372116A1 (en) * 1999-05-14 2000-11-23 Claude Dufresne Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
DE60007697T2 (de) * 1999-07-21 2004-12-09 F. Hoffmann-La Roche Ag Triazolderivate
CA2382789A1 (en) * 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6410556B1 (en) * 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
EP1652839A3 (de) * 1999-10-28 2006-07-05 Daiichi Pharmaceutical Co., Ltd. Pumpeninhibitoren zur Freisetzung von Medikamenten
WO2001046204A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
AU2336001A (en) * 1999-12-22 2001-07-03 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
EP1244677A1 (de) * 1999-12-22 2002-10-02 Merck Frosst Canada Inc. Phosphonsäurediarylerivate als inhibitoren der protein tyrosin phosphatase (ptp-1b)
JP2003518129A (ja) * 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ1b(ptp−1b)のインヒビターとなるホスホン酸誘導体
WO2001053530A1 (en) * 2000-01-18 2001-07-26 Human Genome Sciences, Inc. Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CA2435507A1 (en) * 2000-02-14 2001-08-23 Ceptyr, Inc. Improved assay for protein tyrosine phosphatases
WO2001070754A1 (en) * 2000-03-22 2001-09-27 Merck Frosst Canada & Co. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
US6627647B1 (en) * 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
EP1284260A4 (de) * 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd Tyrosin-phosphatase inhibitoren
DE60135752D1 (en) * 2000-07-06 2008-10-23 Array Biopharma Inc Tyrosinderivate als phosphatase inhibitoren
US20020099073A1 (en) * 2000-07-07 2002-07-25 Andersen Henrik Sune Modulators of protein tyrosine phosphatases (PTPases)
US6613903B2 (en) * 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US20020035137A1 (en) * 2000-08-29 2002-03-21 Gang Liu Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
US6972340B2 (en) * 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
US6472545B2 (en) * 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
US20020169157A1 (en) * 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
GB0022079D0 (en) * 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
JP2002114768A (ja) * 2000-10-11 2002-04-16 Japan Tobacco Inc 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物
BR0114836A (pt) * 2000-10-20 2003-07-01 Pfizer Prod Inc Agonistas de receptores beta-3 adrenérgicos e suas aplicações
US20030108883A1 (en) * 2001-02-13 2003-06-12 Rondinone Cristina M. Methods for identifying compounds that inhibit or reduce PTP1B expression
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US20030064979A1 (en) * 2001-06-29 2003-04-03 Hansen Thomas Kruse Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
US20030170660A1 (en) * 2001-07-11 2003-09-11 Sondergaard Helle Bach P387L variant in protein tyrosine phosphatase-1B is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro
CA2463441A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
US7022730B2 (en) * 2001-10-19 2006-04-04 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
ATE348828T1 (de) * 2001-10-19 2007-01-15 Transtech Pharma Inc Beta-carbolin-derivate als ptp-inhibitoren
JP2003231679A (ja) * 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
CA2469228A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
US6642381B2 (en) * 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
US20030180827A1 (en) * 2002-01-04 2003-09-25 Aventis Pharma Deutschland Gmbh. Highly sensitive and continuous protein tyrosine phosphatase test using 6,8-difluoro-4-methylumbelliferyl phosphate
US20030215899A1 (en) * 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US6784205B2 (en) * 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
CN101597262A (zh) * 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
CN1646508A (zh) * 2002-04-03 2005-07-27 诺瓦提斯公司 作为ptp酶1b抑制剂的5-取代的1,1-二氧代-1,2,5-噻二唑烷-3-酮衍生物
EP1494667A1 (de) * 2002-04-12 2005-01-12 Pfizer Japan Inc. Imidazole derivate zur entzündungshemmung und behandlung von schmerzen
WO2003093498A1 (en) * 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
CA2485093A1 (en) * 2002-05-02 2003-11-13 Neurogen Corporation Substituted imidazole derivatives: gabaa receptor ligands
US20040009946A1 (en) * 2002-05-23 2004-01-15 Ceptyr, Inc. Modulation of PTP1B expression and signal transduction by RNA interference
AU2003246972A1 (en) * 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
US6849761B2 (en) * 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
WO2004062664A1 (en) * 2002-12-30 2004-07-29 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
WO2004071448A2 (en) * 2003-02-12 2004-08-26 Transtech Pharma Inc. Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
WO2005035551A2 (en) * 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
CN101374835B (zh) * 2006-01-30 2012-04-25 转化技术制药公司 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法

Also Published As

Publication number Publication date
NZ548208A (en) 2010-09-30
AU2005214349B2 (en) 2011-11-03
WO2005080346A1 (en) 2005-09-01
JP2007523903A (ja) 2007-08-23
US20050187277A1 (en) 2005-08-25
JP4898458B2 (ja) 2012-03-14
US20110092553A1 (en) 2011-04-21
AU2005214349A1 (en) 2005-09-01
CN1922151A (zh) 2007-02-28
CA2551909C (en) 2011-10-11
CA2551909A1 (en) 2005-09-01
IL176571A0 (en) 2006-10-31
EP1730118A1 (de) 2006-12-13

Similar Documents

Publication Publication Date Title
ZA200605526B (en) Substituted azole derivatives, compositions and methods of use
AU2004210711B2 (en) Substituted azole derivatives as therapeutic agents
US20040186151A1 (en) Substituted azole derivatives as therapeutic agents
FI112942B (fi) Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
CA2040955C (en) Benzimidazole derivatives, their production and use
US11084784B2 (en) ROR-gamma modulators and uses thereof
US7501538B2 (en) Aryl and heteroaryl compounds, compositions and methods of use
JP3099241B2 (ja) ベンズイミダゾール誘導体
EP1991544B1 (de) Substituierte imidazol- derivate und ihre verwendung als ptpase inhibitoren
US20040014778A1 (en) Heteroaryl - fused nitrogen heterocycles as therapeutic agents
CA2855390C (en) 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators
WO2004014844A2 (en) Aryl and heteroaryl compounds and methods to modulate coagulation
EP2324830A1 (de) Verfahren zur Herstellung von einem monozylische Azolderivat das die Interaktion von Liganden mit Rage hemmt
JPH07110854B2 (ja) イミダゾ−ル誘導体およびその製法
US6608210B2 (en) Benzimidazole derivatives, their production and use
MXPA04009961A (es) Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
US20030096826A1 (en) Arylsulfonamide ethers, and methods of use thereof
CA2144019A1 (en) Tetrazolyphenyl pivalate derivatives and medicinal composition containing the same as effective component
RU2788740C2 (ru) 2-цианопиримидин-4-илкарбамат, или производное мочевины, или его соль и содержащая их фармацевтическая композиция
AU2008288648A1 (en) Renin inhibitors
CZ289405B6 (cs) Benzimidazolové deriváty, způsob jejich výroby, farmaceutický prostředek je obsahující a intermediáty pro jejich výrobu